Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) had its price objective hoisted by Robert W. Baird from $105.00 to $121.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's target price would indicate a potential upside of 50.65% from the stock's current price.
Other equities analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Soleno Therapeutics in a report on Tuesday, April 15th. UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Laidlaw boosted their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Cowen started coverage on Soleno Therapeutics in a research report on Monday, June 23rd. They set a "buy" rating on the stock. Finally, Stifel Nicolaus upped their target price on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, March 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Soleno Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $108.70.
View Our Latest Report on Soleno Therapeutics
Soleno Therapeutics Price Performance
SLNO stock opened at $80.32 on Friday. The firm has a market cap of $4.05 billion, a price-to-earnings ratio of -17.39 and a beta of -2.63. The company has a quick ratio of 19.64, a current ratio of 19.64 and a debt-to-equity ratio of 0.21. Soleno Therapeutics has a 12-month low of $41.50 and a 12-month high of $90.32. The company's fifty day simple moving average is $78.71 and its 200 day simple moving average is $62.41.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.19. On average, analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current year.
Insider Transactions at Soleno Therapeutics
In related news, insider Patricia C. Hirano sold 3,830 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the sale, the insider owned 13,206 shares in the company, valued at approximately $1,092,928.56. This trade represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.40% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc grew its position in shares of Soleno Therapeutics by 9.2% during the 4th quarter. Legal & General Group Plc now owns 23,471 shares of the company's stock valued at $1,055,000 after purchasing an additional 1,983 shares in the last quarter. Emerald Advisers LLC grew its position in shares of Soleno Therapeutics by 85.4% during the 4th quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after purchasing an additional 267,585 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Soleno Therapeutics by 13.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock valued at $9,779,000 after purchasing an additional 24,953 shares in the last quarter. Sei Investments Co. grew its position in shares of Soleno Therapeutics by 47.0% during the 4th quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after purchasing an additional 5,258 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Soleno Therapeutics by 4,377.3% during the 1st quarter. GAMMA Investing LLC now owns 3,358 shares of the company's stock valued at $240,000 after purchasing an additional 3,283 shares in the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.
Soleno Therapeutics Company Profile
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Soleno Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.
While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
